ADARx Pharmaceuticals, Inc. ADRX
Nov 5, 2026, 3:38 PM EST
- YTD
- -30.75%
- 1 year
- -30.75%
- Market cap
- 1.49B
- Revenue (ttm)
- 6.13M
- EPS (ttm)
- -1.16
- Shares out
- 110.74M
- Forward P/E
- -9.86
- YTD return
- -30.75%
- 1-year return
- -30.75%
- Volume
- 653.94K
- Avg volume
- 670.04K
- Open
- 14.97
- Previous close
- 14.96
- Day's range
- 13.33 – 15.39
- 52-week range
- 13.33 – 23.21
- Analysts
- Strong Buy
- Price target
- 34.25 (+155.6%)
2Y -5.31 (-27.44%)
Key statistics
- Enterprise value
- 1.65B
- PEG ratio
- 0.00
- Price / sales
- 269.66
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 258.70%
- Free cash flow
- 0
- Total cash
- 427.25M
- Total debt
- 6.90M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 18.05
- 200-day average
- 18.05
Analyst view
Consensus: strong buy
- Target (low)
- 32.00
- Target (mean)
- 34.25
- Target (high)
- 38.00
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.36348.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Sep 2, 2026 | Sep 30, 2026 | — | -2.27 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 20, 2026 | TD Cowen | init | — | Buy |
| Oct 20, 2026 | JP Morgan | init | — | Overweight |
| Oct 20, 2026 | UBS | init | — | Buy |
| Oct 20, 2026 | Morgan Stanley | init | — | Overweight |
About ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer's disease. The company was incorporated in 2019 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- adarx.com
News
JP Morgan Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $38 
This Restaurant Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday 
UBS Initiates Coverage On Adarx Pharmaceuticals with Buy Rating, Announces Price Target of $35 
Morgan Stanley Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $32 
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering 
First Look: Disney Layoffs, Apple Smart Home Launch, Goldman CEO Talks 
ADARx Pharmaceuticals raises $446.3 million in upsized US IPO 
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
Your note
Sign in to keep a note on ADRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHIMOVITS EREZ | Director | Purchase | Sep 27, 2026 | 0 |
| GEORGE SIMEON J. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 27, 2026 | 0 |
| GORDON CARL L | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 27, 2026 | 0 |
| LAV BIOSCIENCES FUND V LP | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 27, 2026 | 0 |
| ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 27, 2026 | 0 |
| SR ONE CAPITAL MANAGEMENT, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 27, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Laurion Capital Management, LP | 0.02% | 20,000 | 298.40K | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 3.18% | 3,246,801 | 48.44M | Sep 29, 2026 |
| American Funds-SmallCap World Fund | 0.08% | 85,500 | 1.28M | Sep 29, 2026 |
| Federated Hermes Index Trust-Federated Hermes Max-Cap Index Fund | 0.00% | 225 | 3.36K | Sep 29, 2026 |
| Federated Hermes Index Trust-Federated Hermes Mid-Cap Index Fund | 0.00% | 220 | 3.28K | Sep 29, 2026 |
| Federated Hermes Income Securities TRT-Federated Hermes Muni and Stock | 0.00% | 2,089 | 31.17K | Sep 29, 2026 |